Wedbush Assumes Coverage on eBay (EBAY) at Neutral; Q2 Beat as GSI Is Integrated
Tweet
Share
E-mailGet Alerts EBAY Hot Sheet
Price: $100.94 --0%
Rating Summary:
23 Buy, 28 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 10 | New: 23
Rating Summary:
23 Buy, 28 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 10 | New: 23
Join SI Premium – FREE
Wedbush assumes coverage on eBay (NASDAQ: EBAY) with a Neutral. PT $35 (from $34)
Wedbush analyst says, "We believe eBay can maintain double-digit organic top line growth as the Marketplaces business turns around and PayPal growth accelerates...Non-motors GMV growth suggests continued improvement in Marketplaces business...Operating margin decline due mainly to mix shift to lower margin businesses and acquisitions...Full-year guidance revised upward to reflect better operating performance and integration of GSI...Raising 2011 estimates to $2.02 from $1.95 and to $2.33 from $2.20 for 2012 based on better-than-expected results."
For more ratings news on eBay click here and for the rating history of eBay click here.
Shares of eBay closed at $33.76 yesterday.
Wedbush analyst says, "We believe eBay can maintain double-digit organic top line growth as the Marketplaces business turns around and PayPal growth accelerates...Non-motors GMV growth suggests continued improvement in Marketplaces business...Operating margin decline due mainly to mix shift to lower margin businesses and acquisitions...Full-year guidance revised upward to reflect better operating performance and integration of GSI...Raising 2011 estimates to $2.02 from $1.95 and to $2.33 from $2.20 for 2012 based on better-than-expected results."
For more ratings news on eBay click here and for the rating history of eBay click here.
Shares of eBay closed at $33.76 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Barclays Starts Centrus Energy Corp. (LEU) at Equalweight
- Leerink Starts Scribe Therapeutics Inc (SCTX) at Outperform
- Barclays Starts Enliven Therapeutics (ELVN) at Overweight
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
